Qaytarish

Saraton antigeni (CA 125)

Kod:10004|CPT:86304|LOINC:10334-1

Sinonimlar
CA 125Second Generation Assay
KabiSaraton antigeni (CA 125)

Tahlil ma'lumotlari

Tadqiqot usuli

  • Elektrokimyoluminessent immunoanaliz (ECLIA)

Kutilayotgan natija topshirish vaqti

1 kun

Maxsus tayyorlik

  • Do not smoke during the 30 minutes before the blood draw.
  • For serial follow‑up, use the same assay methodology each time; avoid comparing results produced by different methods.
  • If taking high‑dose biotin supplements, stop for at least 72 hours before specimen collection.

Qanday foydalanish

CA 125 (CA‑125) mos klinik kontekstda epitelial tuxumdon saratonini aniqlashga ko‘maklashish, kasallik kechishini va davolashga javobni monitoring qilish hamda tuxumdon saratoni qaytalanishini aniqlash uchun qo‘llanadi. CA 72‑4 yoki HE4 kabi boshqa o‘smа markerlari bilan birgalikda qo‘llanganda, umumiy diagnostik sezgirlik yuqoriroq bo‘lishi mumkin.

Cheklovlar

Tuxumdon saratoni ayollardagi malign neoplaziyalarning taxminan 4% dan 6% gacha qismini tashkil etadi va ko‘pincha erta davrda xos alomatlarsiz namoyon bo‘ladi. Bunday vaziyatda o‘sma markerlari fizik ko‘rik va tasvirlash usullarini to‘ldiradi. CA 125 — tuxumdon epitelial o‘sma hujayralarida mavjud bo‘lgan va, shuningdek, normal to‘qimalarda, jumladan perikard, plevra, peritoney, endometriy va moyaklarda uchraydigan yuqori molekulyar og‘irlikdagi glikoproteindir. Qon zardobida sezilarli oshishlar tuxumdon malignitetida keng tarqalgan va boshqa saratonlarda (masalan, endometriy, kolorektal, o‘pka, sut bezi, oshqozon osti bezi) kamroq uchraydi. Ekspressiya va zardob darajasining oshishi sog‘lom ayollarda ham, shuningdek benign yoki yallig‘lanish kasalliklarida — masalan, benign tuxumdon va bachadon kasalliklari, endometrioz, peritonit, plevrit, surunkali gepatit yoki sirroz, va surunkali pankreatitda — kuzatilishi mumkin; shu bois talqin qilishda klinik kontekst zarur. Postmenopauza davridagi ayollarda ko‘rsatkichning doimiy yuqori bo‘lishi malign epitelial tuxumdon o‘smalari bilan kuchliroq bog‘liq. CA 72‑4 musinoz tuxumdon karsinomasida va boshqa adenokarsinomalarda oshishi mumkin; CA 125 ni CA 72‑4 bilan birga baholash diagnostik sezgirlikni taxminan 73% gacha oshirishi haqida xabar qilingan.

Referens oraliq
ErkaklarAyollar
0–200–35
Ko'rsatmalarWorkup of a possible ovarian tumor, Assisting in distinguishing benign from malignant ovarian masses, Postoperative evaluation of therapeutic effectiveness, Assessment when metastatic spread is suspected, Testing in individuals with high‑risk human papillomavirus identified by PCR

Natija og'ishlarining mumkin sabablari

Pasaygan daraja

  • biotin

Namunangiz talablari

NamunangizZardob
ContainerOltin/yo'lbars qopqoqli probirka (SST, gel ajratgich)
Hajm1 mL (min 0.7 mL)
Saqlash tayyorlikXona harorati, Sovutilgan, Muzlatilgan

References

Kozachenko VP. Treatment of patients with ovarian cancer. Russian Medical Journal. 2003;26:1458.

Urmanceeva AF, Meshkova IE. Issues of epidemiology and diagnosis of ovarian cancer. Medical Academy of Postgraduate Education, N.N. Petrov Research Institute of Oncology, St. Petersburg.

Cancer Incidence in Five Continents. IARC Scientific Publications. Lyon; 1997; Vol. 7:143.